

PROLIGHT DIAGNOSTICS SHOWS PROOF OF PERFORMANCE IN WHOLE BLOOD

Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample.

“This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single molecule counting platform that can function with whole blood. The ability to measure in whole blood, without a cell-separation step, reduces complexity, paving the way for an extremely competitive price level”, said Ulf Bladin, CEO of Prolight.

Prolight’s point-of-care troponin assay is developed to facilitate more rapid rule-in and rule-out of myocardial infarction (MI). The company has now demonstrated the ability to quantitatively measure in the single digit nanogram per litre range in whole blood. Fresh human blood samples were spiked using pooled plasma from patients with known elevated troponin levels post-MI. The troponin concentrations in the blood samples were confirmed by measuring them in parallel on a commercially available high-sensitivity troponin assay.

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: info@prolightdx.com

Telephone: +46 73 582 39 87

Website: www.prolightdx.com/en/

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Prolight Diagnostics shows proof of performance in whole blood](#)